Advertisement
Canada markets close in 44 minutes

  • S&P/TSX

    21,980.46
    +95.08 (+0.43%)
     

  • S&P 500

    5,109.59
    +61.17 (+1.21%)
     

  • DOW

    38,284.98
    +199.18 (+0.52%)
     

  • CAD/USD

    0.7321
    -0.0003 (-0.03%)
     

  • CRUDE OIL

    83.75
    +0.18 (+0.22%)
     

  • Bitcoin CAD

    87,369.37
    -900.60 (-1.02%)
     

  • CMC Crypto 200

    1,333.90
    -62.64 (-4.49%)
     

  • GOLD FUTURES

    2,350.40
    +7.90 (+0.34%)
     

  • RUSSELL 2000

    2,003.66
    +22.54 (+1.14%)
     

  • 10-Yr Bond

    4.6690
    -0.0370 (-0.79%)
     

  • NASDAQ

    15,948.51
    +336.75 (+2.16%)
     

  • VOLATILITY

    14.96
    -0.41 (-2.67%)
     

  • FTSE

    8,139.83
    +60.97 (+0.75%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6837
    +0.0016 (+0.23%)
     
MARKETS LIVE BLOG:

STOCKS RISE, LED BY STELLAR ALPHABET, MICROSOFT EARNINGS

Latest stubborn U.S. inflation reading will bring about more 'wait and see' from the Fed

Why Shares of BeiGene Popped Today

Alex Carchidi, The Motley Fool
·1 min read

BeiGene's (NASDAQ: BGNE) shares were up by more than 13% on Tuesday at 2:50 p.m. ET thanks to a regulatory body in China accepting one of the company's supplemental biologics licensing application filings for a new indication for its drug tislelizumab. The Center for Drug Evaluation (CDE) will now evaluate whether tislelizumab is sufficiently safe and effective to treat metastatic gastric junction adenocarcinoma in conjunction with chemotherapy for patients whose tumors express the PD-1 biomarker, potentially giving BeiGene the green light for an expansion of its commercialization in China. If regulators ultimately opt to approve the company's application, it'll be the 10th indication for tislelizumab in China, which speaks to its versatility as a cancer medicine as well as its money-making potential.

Continue reading